- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Prior treatment with and failure of at least one regimen of chemotherapy and
- Prior treatment with no more than two chemotherapy regimens, including adjuvant or
combined modality treatment.
- Measurable disease .
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- Tissue available for KRAS/ EGFR testing
- Creatinine clearance > 40 cc/min or serum creat
- Biological or investigational agents within 4 weeks of baseline disease assessment.
- Patients who lack of tolerance of erlotinib therapy.